Considering biomarkers in asthma disease severity.

Abstract excerpt

Among patients with asthma, reliance on the type/dose of prescribed medication and symptom control does not adequately capture those at risk of adverse outcomes, and we need biomarkers for risk and treatment stratification that are consistently accurate, readily quantifiable, and reproducible. Most patients with severe asthma, regardless of age, have predominant type-2 inflammation-mediated disease, making...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetic Predisposition to Disease
• Share to Severity of Illness Index
• Share to Asthma